Clincosm LogoSign in Get a demo

HER2-negative Breast Cancer

Showing 26 - 50 of 91
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-negative Breast Cancer, Advanced Breast Cancer, Hormone Receptor-positive Breast Cancer Trial in India, United States (Part

Recruiting
  • HER2-negative Breast Cancer
  • +2 more
  • Part 1
  • +2 more
  • Los Angeles, California
  • +11 more
Oct 29, 2022

Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma Trial in Boston (Onvansertib, Paclitaxel)

Recruiting
  • Breast Cancer
  • +9 more
  • Boston, Massachusetts
  • +2 more
Oct 25, 2022

Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Trial in Madison (18F-DCFPyL)

Recruiting
  • Breast Cancer
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin School of Medicine and Public Health
Oct 18, 2022

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +5 more
  • PI3K inhibitor BYL719
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 14, 2022

HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine

Recruiting
  • HER2-negative Breast Cancer
  • +5 more
  • Camrelizumab with vinorelbine and cisplatin
  • Beijing, Beijing, China
    Peking University First Hospital
Oct 15, 2022

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Immune Environment in Response to Therapy in Breast Cancer

Recruiting
  • Breast Cancer
  • +3 more
  • Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
  • Philadelphia, Pennsylvania
    Abramson Cancer Center
Sep 15, 2022

HER2-negative Breast Cancer Trial in China (BGB-290)

Completed
Has Results
  • HER2-negative Breast Cancer
  • Beijing, Beijing, China
  • +21 more
Mar 28, 2022

ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer Trial (Elacestrant, Tamoxifen, Letrozole 2.5mg)

Not yet recruiting
  • ER-positive Breast Cancer
  • +3 more
  • (no location specified)
Aug 22, 2022

Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)

Not yet recruiting
  • Metastatic Breast Cancer
  • +3 more
  • (no location specified)
Aug 18, 2022

Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer Trial in Netherlands (Fasting

Not yet recruiting
  • Fasting Mimicking Diet
  • +5 more
  • Fasting Mimicking diet program
  • Alkmaar, Netherlands
  • +14 more
Aug 15, 2022

Breast Cancer, Breast Tumors, Breast Tumor Female Trial in Germany (Ribociclib)

Not yet recruiting
  • Breast Cancer
  • +6 more
  • Erlangen, Bavaria, Germany
  • +15 more
Aug 10, 2022

2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2-

Recruiting
  • Advanced Breast Cancer
  • +2 more
    • Ancona, Italy
    • +28 more
    Jul 27, 2022

    Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,

    Not yet recruiting
    • Locoregional Recurrence
    • +2 more
    • (no location specified)
    Jul 18, 2022

    ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer Trial in Madison, Milwaukee (Onapristone, Fulvestrant)

    Recruiting
    • ER-positive Breast Cancer
    • +2 more
    • Madison, Wisconsin
    • +1 more
    Jul 7, 2022

    Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer Trial in

    Recruiting
    • Hormone Receptor Positive Breast Carcinoma
    • +2 more
    • Chicago, Illinois
    • +2 more
    Jul 1, 2022

    HER2-negative Breast Cancer, Advanced Solid Tumor Trial in Singapore (ADG106, Doxorubicin, Cyclophosphamide)

    Recruiting
    • HER2-negative Breast Cancer
    • Advanced Solid Tumor
    • Singapore, Singapore
      National University Hospital
    Jun 9, 2022

    Ewing Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma Trial in United States (PRT2527)

    Recruiting
    • Ewing Sarcoma
    • +7 more
    • Denver, Colorado
    • +5 more
    Jun 9, 2022

    ER+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer Trial in United States (BLU-222, Carboplatin, Ribociclib)

    Recruiting
    • ER+ Breast Cancer
    • +8 more
    • Sarasota, Florida
    • +3 more
    Jun 8, 2022

    HER2-negative Breast Cancer Trial in Salt Lake City (Precision Medicine, Physican Decision Making)

    Recruiting
    • HER2-negative Breast Cancer
    • Precision Medicine
    • Physican Decision Making
    • Salt Lake City, Utah
      Huntsman Cancer Institute at University of Utah
    Jun 9, 2022

    ER+ Breast Cancer, HER2-negative Breast Cancer Trial in Christchurch, London, Oxford (Palbociclib 125Mg Tab, Fulvestrant

    Recruiting
    • ER+ Breast Cancer
    • HER2-negative Breast Cancer
    • Palbociclib 125Mg Tab
    • +5 more
    • Christchurch, United Kingdom
    • +3 more
    May 19, 2022

    Invasive Lobular Breast Carcinoma, ER+ Breast Cancer, HER2-negative Breast Cancer Trial in Belgium, France (Entrectinib,

    Recruiting
    • Invasive Lobular Breast Carcinoma
    • +2 more
    • Brussels, Belgium
    • +9 more
    May 4, 2022

    Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer Trial in

    Terminated
    Has Results
    • Estrogen Receptor-negative Breast Cancer
    • +6 more
    • Baltimore, Maryland
      University of Maryland Baltimore
    Apr 29, 2022

    HER2-negative Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer Trial in Spain (Olaparib)

    Recruiting
    • HER2-negative Breast Cancer
    • +2 more
    • Barcelona, Spain
    • +4 more
    Apr 14, 2022

    Anlotinib Combined With Chemotherapy for Treatment of HER2

    Not yet recruiting
    • HER2-negative Breast Cancer
      • (no location specified)
      Apr 18, 2022